The need for predictive, prognostic, objective and complementary blood-based biomarkers in osteoarthritis (OA) by Bay-Jensen, A-C et al.
EBioMedicine 7 (2016) 4–6
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comIn FocusThe Need for Predictive, Prognostic, Objective and Complementary
Blood-Based Biomarkers in Osteoarthritis (OA)Anne-C. Bay-Jensen a, Yves Henrotin b,c, Morten Karsdal a,d, Ali Mobasheri e,f,g,h,i,⁎,1
a Rheumatology, Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
b Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège, Institute of Pathology, Liège, Belgium
c Physical Therapy and Rehabilitation Department, Princess Paola Hospital, Marche-en-Famenne, Belgium
d Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom
e Department of Cancer and Inﬂammation Research, University of Southern Denmark, Copenhagen, Denmark
f Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis, Queen's Medical Centre, Nottingham, United Kingdom
g Center of Excellence in Genomic Medicine Research (CEGMR), King Fahd Medical Research Center (KFMRC), King Abdul Aziz University, Jeddah, Saudi Arabia
h Arthritis Research UK Pain Centre, Queen's Medical Centre, Nottingham, United Kingdom
i Medical Research Council and Arthritis Research UK Centre for Musculoskeletal Ageing Research, Queen's Medical Centre, Nottingham, United KingdomOsteoarthritis (OA) has traditionally been viewed as a non- and characterization of the individual patient will adversely inﬂuence
inﬂammatory arthropathy and has not been considered a ‘serious dis-
ease’. However, this view has radically changed in recent years, due to
the complexity and heterogeneity of the patient populations, spiralling
socio-economical costs and long-term impact on the quality of life of af-
fected individuals. There is an acute need for objective and non-invasive
diagnostic biomarkers in OA, markers that can stratify patient subtypes
and thereby direct therapeutic treatments at an earlier disease stage
(read personal health care (PHC)) (Conaghan, 2013). Increased interest
in the development of new diagnostic and prognostic tests for early
forms of OA may incorporate the use of blood-based biomarkers; how-
ever, both research and regulated development and approval are still
needed to reach a diagnostically important signiﬁcant point where a
given biomarker will beneﬁt the clinical management of the patient.
1. The OA Biomarker Landscape Today
There are currently no disease-modifying osteoarthritis drugs
(DMOAD) available for treatment of OA patients (Mobasheri, 2013;
Qvist et al., 2008). This may be due to the heterogeneity of the OA pop-
ulation,where the origin and driver of disease progression is often poor-
ly understood. The main treatment options for OA presently are pain
relief, physical therapy and nutritional supplements (nutraceuticals).
However, none of these can halt or reverse disease progression. In addi-
tion, diagnosis is often subjective, due to the lack of objective, precise
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horts for the testing of drugs in clinical trials. There is a medical need
for objective, precise and accurate in vitro diagnostic devices for clinical
trial enrichment (Kraus et al., 2015; Karsdal et al., 2013).2. What Is the Medical Need for Biomarkers?
The lack of approvedDMOADs in OAdrags a long tail of failed clinical
drug trials. Recently the US Food and Drug Administration (FDA), the
European Medicines Agency (EMA) and other regulatory agencies
have published guidelines on howbiomarkers should bedeﬁned. Differ-
ent groups and public-private partnerships have proposed different
models for classifying OA biomarkers for clinical use (Bauer et al.,
2006; Kraus et al., 2011; Bay-Jensen et al., 2016a,b). There is a general
consensus on the medical need for biomarker development which
may be summarized as seven key points:
1. Translational biomarkers, which allow better characterization of a
drug in preclinical development, ensuring of selection of the most
viable projects
2. Early identiﬁcation of efﬁcacy of intervention; Go/no-go decision-
making already in phase 1b/2a studies, which normally do not
include efﬁcacy measures.
3. Phase II and Phase III trial enrichment; reduction in study size, and a
particular OA phenotype tailored for a selective interventions, which
will recuse length of the clinical study to allowmore efﬁcient and less
costly trials
4. Identiﬁcation of patients who are fast progressors and as such in
greatest need of treatment.
5. Identiﬁcation of super responders to a speciﬁc treatment; patients
with high efﬁcacy and low safety concernsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
5A.-C. Bay-Jensen et al. / EBioMedicine 7 (2016) 4–66. Biomarkers of disease activity; as OA is not a stabile disease, there is a
need for devices for identiﬁcation with high disease activity and
potential progression
7. Easy accessible monitoring devices – point of care; post marketing
patient care and personalized medicine
Although there are clear overlaps in the above, it is clear that no
single biomarker will be the answer for all.
3. Message From the Regulators
The public attention to biomarkers is increasing, recently further
emphasized by the “white house” initiate focusing on quantiﬁable
tools for patient election and monitoring.2 On the regulatory side, the
FDA issued a position document describing the need and road ahead
for personalized medicine “FDA: Paving the Way for Personalized
Medicine”,3 which later resulted in new guidelines to faster biomarker
tool development by the guidelines “Identifying Potential Biomarkers
for Qualiﬁcation and Describing Contexts of Use To Address Areas
Important to Drug Development”,4 which are in addition to the
standard guidelines for in vitro companion diagnostic device. This has
led to the discussion on prospective-retrospective biomarker analysis
for regulatory consideration, by the white paper from the industry
pharmacogenomics working group (Patterson et al., 2011). This will
greatly assist precision medicine and PHC by guiding the discussion on
how to implement a “prospective-retrospective biomarker analysis”.
The prospective-retrospective biomarker analysis approach is
developed to “rescue” failed phase III trials. Qualiﬁed biomarkers are
to be measured in certiﬁed, high-quality laboratories and analyzed
using predeﬁned statistical analysis plans to test hypotheses related to
retrospective analysis of technically and biologically validated
biomarkers.
According to the FDA, a prognostic in vitro diagnostic biomarker
would need a 510 K or de novo approval (class II device), whereas a
predictive biomarker would need ldt pre-market approval (PMA, class
III device). The main separating factor is that a prognostic biomarker
provides you with an estimate for progression, whereas a predictive
biomarker would be used to decide the exact treatment regimen for
individual patients, and would therefore have a signiﬁcant impact on
the patient's life. A predictive biomarkerwill often become a companion
diagnostic.5 In addition, the recent “drug development tool (DDT) box”
guidelines are also allowing for regulatory assessment of tools to assist
in clinical drug development, such as the ﬁbrinogen enrichment of
patients in COPD clinical studies with a more severe outcome (fast
progressors), which is now classiﬁed as a DDT.
No biomarkers have yet been qualiﬁed as biomarkers for OA,
however several biomarkers have been developed targeting cartilage
degradation and formation (e.g. CTX-II, ARGS, PIIANP), joint
inﬂammation (e.g. C3M, Col2-NO2), bone remodelling (e.g. alpha
CTX\\I, osteocalcin) as well as inﬂammation and metabolic factors
(Bay-Jensen et al., 2016a,b). The scientists and clinicians working in
the biomarker ﬁeld cannot expect a “one size ﬁts all” solution for OA.
Consequently it is important to test and validate a biomarker to a specif-
ic hypothesis. This can be done under the laboratory-developed test2 TheWhite house, 2015. Precision Medicine Initiative | TheWhite House [WWWDoc-
ument]. White house. URL https://www.whitehouse.gov/precision-medicine (accessed
2.5.16).
3 FDA, 2013. Paving theWay for PersonalizedMedicine [WWWDocument]. URL http://
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UCM372421.pdf (accessed 2.5.16).
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of Use To Address Areas Important to Drug Development; Request for Comments [WWW
Document]. FDA. URL https://www.federalregister.gov/articles/2015/02/13/2015-02976/
identifying-potential-biomarkers-for-qualiﬁcation-and-describing-contexts-of-use-to-
address-areas (accessed 2.5.16)
5 FDA, 2014. In Vitro Companion Diagnostic Devices. Guidance for Industry and Food
and Drug Administration Staff.(LDT) (Sarata and Johnson, 2014), which is a type of in vitro diagnostic
test that is designed, manufactured and used within a single laboratory.
4. How Do WeMove Forward?
Different approaches, techniques and better-stratiﬁed patient
samples are needed tomove biomarker development towards qualiﬁca-
tion, which means that new partners need to come together and
collaborate. For example development of a novel blood-based and
cartilage-derived protein biomarker requires application of advanced
analytical techniques such as proteomics and mass spectrometry,
whereas development of the biomarker assay requires knowhow of
biochemical and immunological assessment platforms. Furthermore,
testing, validation and qualiﬁcation requires access to high quality
clinical samples from several independent retrospective or prospective
cohorts. In the end a commercialisation plan needs to be established
to push forwards and ﬁnance the qualiﬁcation of biomarkers. Thus it is
most likely that no single entity, public or private, will be able to
complete these development steps alone. There is a need for
i) Formation of public-private partnerships to develop, test, validate
and qualify biomarkers for use in clinical trial and patient management,
ii) Design of clinical studies that stratify patients and investigate trends
and characteristics of speciﬁc OA cohorts and study populations, and iii)
Collaboration between biotech and pharmaceutical companies to
support the commercialization of biomarkers.
In summary, a great deal of collaborative work needs to be done in
this area to develop more predictive, prognostic, objective and comple-
mentary biomarkers for OA management and DMOAD development.
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